nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Skin infection—Mitoxantrone—sarcoma	0.0479	0.0601	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PLCG1—sarcoma	0.0461	0.227	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Thiotepa—sarcoma	0.0282	0.0353	CcSEcCtD
Methyl aminolevulinate—FCGR1A—FCGR activation—SRC—sarcoma	0.0258	0.127	CbGpPWpGaD
Methyl aminolevulinate—Sensitisation—Epirubicin—sarcoma	0.0189	0.0237	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PLCG1—sarcoma	0.018	0.0886	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Dactinomycin—sarcoma	0.0176	0.022	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Doxorubicin—sarcoma	0.0175	0.0219	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Thiotepa—sarcoma	0.0165	0.0208	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Thiotepa—sarcoma	0.016	0.0201	CcSEcCtD
Methyl aminolevulinate—Ulcer—Mitoxantrone—sarcoma	0.0153	0.0192	CcSEcCtD
Methyl aminolevulinate—Ulcer—Etoposide—sarcoma	0.0127	0.016	CcSEcCtD
Methyl aminolevulinate—Swelling—Mitoxantrone—sarcoma	0.0119	0.0149	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Etoposide—sarcoma	0.0115	0.0144	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Epirubicin—sarcoma	0.0113	0.0142	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Doxorubicin—sarcoma	0.0105	0.0132	CcSEcCtD
Methyl aminolevulinate—Keratitis—Epirubicin—sarcoma	0.0104	0.013	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—PLCG1—sarcoma	0.01	0.0492	CbGpPWpGaD
Methyl aminolevulinate—Swelling—Etoposide—sarcoma	0.0099	0.0124	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Epirubicin—sarcoma	0.0097	0.0122	CcSEcCtD
Methyl aminolevulinate—Keratitis—Doxorubicin—sarcoma	0.00962	0.0121	CcSEcCtD
Methyl aminolevulinate—Blister—Epirubicin—sarcoma	0.00935	0.0117	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Doxorubicin—sarcoma	0.00898	0.0113	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Epirubicin—sarcoma	0.00866	0.0109	CcSEcCtD
Methyl aminolevulinate—Blister—Doxorubicin—sarcoma	0.00865	0.0109	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Vincristine—sarcoma	0.0085	0.0107	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Epirubicin—sarcoma	0.00845	0.0106	CcSEcCtD
Methyl aminolevulinate—Stinging—Epirubicin—sarcoma	0.00832	0.0104	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Doxorubicin—sarcoma	0.00801	0.0101	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Thiotepa—sarcoma	0.00786	0.00986	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Doxorubicin—sarcoma	0.00782	0.00982	CcSEcCtD
Methyl aminolevulinate—Stinging—Doxorubicin—sarcoma	0.0077	0.00966	CcSEcCtD
Methyl aminolevulinate—Erythema—Thiotepa—sarcoma	0.00732	0.00919	CcSEcCtD
Methyl aminolevulinate—Erythema—Dactinomycin—sarcoma	0.00726	0.00912	CcSEcCtD
Methyl aminolevulinate—Ulcer—Epirubicin—sarcoma	0.00713	0.00895	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PLCG1—sarcoma	0.00668	0.0329	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis contact—Epirubicin—sarcoma	0.00666	0.00836	CcSEcCtD
Methyl aminolevulinate—Ulcer—Doxorubicin—sarcoma	0.0066	0.00828	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Epirubicin—sarcoma	0.00644	0.00808	CcSEcCtD
Methyl aminolevulinate—Erythema—Mitoxantrone—sarcoma	0.00632	0.00793	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Doxorubicin—sarcoma	0.00617	0.00774	CcSEcCtD
Methyl aminolevulinate—Discomfort—Dactinomycin—sarcoma	0.00611	0.00767	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—sarcoma	0.00598	0.0294	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Doxorubicin—sarcoma	0.00596	0.00747	CcSEcCtD
Methyl aminolevulinate—Infection—Thiotepa—sarcoma	0.00593	0.00745	CcSEcCtD
Methyl aminolevulinate—Oedema—Dactinomycin—sarcoma	0.00593	0.00744	CcSEcCtD
Methyl aminolevulinate—Infection—Dactinomycin—sarcoma	0.00589	0.00739	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Etoposide—sarcoma	0.00564	0.00708	CcSEcCtD
Methyl aminolevulinate—Eczema—Epirubicin—sarcoma	0.00545	0.00683	CcSEcCtD
Methyl aminolevulinate—Eye pain—Epirubicin—sarcoma	0.00542	0.0068	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Thiotepa—sarcoma	0.00536	0.00673	CcSEcCtD
Methyl aminolevulinate—Discomfort—Mitoxantrone—sarcoma	0.00532	0.00667	CcSEcCtD
Methyl aminolevulinate—Oedema—Vincristine—sarcoma	0.0053	0.00665	CcSEcCtD
Methyl aminolevulinate—Infection—Vincristine—sarcoma	0.00526	0.0066	CcSEcCtD
Methyl aminolevulinate—Oedema—Mitoxantrone—sarcoma	0.00516	0.00647	CcSEcCtD
Methyl aminolevulinate—Fatigue—Thiotepa—sarcoma	0.00515	0.00646	CcSEcCtD
Methyl aminolevulinate—Infection—Mitoxantrone—sarcoma	0.00513	0.00643	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Epirubicin—sarcoma	0.00512	0.00643	CcSEcCtD
Methyl aminolevulinate—Fatigue—Dactinomycin—sarcoma	0.00511	0.00641	CcSEcCtD
Methyl aminolevulinate—Pain—Thiotepa—sarcoma	0.00511	0.00641	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD34—sarcoma	0.00508	0.025	CbGpPWpGaD
Methyl aminolevulinate—Pain—Dactinomycin—sarcoma	0.00507	0.00636	CcSEcCtD
Methyl aminolevulinate—Eczema—Doxorubicin—sarcoma	0.00504	0.00632	CcSEcCtD
Methyl aminolevulinate—Eye pain—Doxorubicin—sarcoma	0.00502	0.00629	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Vincristine—sarcoma	0.00476	0.00597	CcSEcCtD
Methyl aminolevulinate—Urticaria—Thiotepa—sarcoma	0.00475	0.00596	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Doxorubicin—sarcoma	0.00474	0.00595	CcSEcCtD
Methyl aminolevulinate—Face oedema—Epirubicin—sarcoma	0.00472	0.00593	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Mitoxantrone—sarcoma	0.00463	0.00581	CcSEcCtD
Methyl aminolevulinate—Fatigue—Vincristine—sarcoma	0.00457	0.00573	CcSEcCtD
Methyl aminolevulinate—Pain—Vincristine—sarcoma	0.00453	0.00568	CcSEcCtD
Methyl aminolevulinate—Fatigue—Mitoxantrone—sarcoma	0.00445	0.00558	CcSEcCtD
Methyl aminolevulinate—Discomfort—Etoposide—sarcoma	0.00442	0.00555	CcSEcCtD
Methyl aminolevulinate—Pain—Mitoxantrone—sarcoma	0.00441	0.00554	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Thiotepa—sarcoma	0.0044	0.00552	CcSEcCtD
Methyl aminolevulinate—Face oedema—Doxorubicin—sarcoma	0.00437	0.00549	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Dactinomycin—sarcoma	0.00437	0.00548	CcSEcCtD
Methyl aminolevulinate—Asthenia—Thiotepa—sarcoma	0.00429	0.00538	CcSEcCtD
Methyl aminolevulinate—Infection—Etoposide—sarcoma	0.00426	0.00535	CcSEcCtD
Methyl aminolevulinate—Asthenia—Dactinomycin—sarcoma	0.00425	0.00534	CcSEcCtD
Methyl aminolevulinate—Pruritus—Thiotepa—sarcoma	0.00423	0.0053	CcSEcCtD
Methyl aminolevulinate—Urticaria—Mitoxantrone—sarcoma	0.0041	0.00514	CcSEcCtD
Methyl aminolevulinate—Dizziness—Thiotepa—sarcoma	0.00395	0.00496	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Vincristine—sarcoma	0.0039	0.0049	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Epirubicin—sarcoma	0.00386	0.00485	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Etoposide—sarcoma	0.00385	0.00484	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Mitoxantrone—sarcoma	0.0038	0.00477	CcSEcCtD
Methyl aminolevulinate—Asthenia—Vincristine—sarcoma	0.0038	0.00477	CcSEcCtD
Methyl aminolevulinate—Rash—Thiotepa—sarcoma	0.00377	0.00473	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Thiotepa—sarcoma	0.00376	0.00472	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PLCG1—sarcoma	0.00374	0.0184	CbGpPWpGaD
Methyl aminolevulinate—Headache—Thiotepa—sarcoma	0.00374	0.0047	CcSEcCtD
Methyl aminolevulinate—Rash—Dactinomycin—sarcoma	0.00374	0.00469	CcSEcCtD
Methyl aminolevulinate—Asthenia—Mitoxantrone—sarcoma	0.0037	0.00465	CcSEcCtD
Methyl aminolevulinate—Fatigue—Etoposide—sarcoma	0.0037	0.00464	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PTPRC—sarcoma	0.00367	0.0181	CbGpPWpGaD
Methyl aminolevulinate—Pain—Etoposide—sarcoma	0.00367	0.00461	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PLCG1—sarcoma	0.00359	0.0177	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Doxorubicin—sarcoma	0.00357	0.00448	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ATF1—sarcoma	0.00356	0.0175	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Thiotepa—sarcoma	0.00355	0.00445	CcSEcCtD
Methyl aminolevulinate—Nausea—Dactinomycin—sarcoma	0.00352	0.00442	CcSEcCtD
Methyl aminolevulinate—Dizziness—Vincristine—sarcoma	0.0035	0.0044	CcSEcCtD
Methyl aminolevulinate—Urticaria—Etoposide—sarcoma	0.00341	0.00428	CcSEcCtD
Methyl aminolevulinate—Rash—Vincristine—sarcoma	0.00334	0.00419	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Vincristine—sarcoma	0.00334	0.00419	CcSEcCtD
Methyl aminolevulinate—Headache—Vincristine—sarcoma	0.00332	0.00416	CcSEcCtD
Methyl aminolevulinate—Rash—Mitoxantrone—sarcoma	0.00325	0.00408	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mitoxantrone—sarcoma	0.00325	0.00408	CcSEcCtD
Methyl aminolevulinate—Headache—Mitoxantrone—sarcoma	0.00323	0.00406	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Epirubicin—sarcoma	0.00316	0.00397	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Etoposide—sarcoma	0.00316	0.00397	CcSEcCtD
Methyl aminolevulinate—Nausea—Vincristine—sarcoma	0.00315	0.00395	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CD34—sarcoma	0.00308	0.0152	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Etoposide—sarcoma	0.00308	0.00386	CcSEcCtD
Methyl aminolevulinate—Nausea—Mitoxantrone—sarcoma	0.00306	0.00385	CcSEcCtD
Methyl aminolevulinate—Pruritus—Etoposide—sarcoma	0.00304	0.00381	CcSEcCtD
Methyl aminolevulinate—Erythema—Epirubicin—sarcoma	0.00295	0.0037	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Doxorubicin—sarcoma	0.00293	0.00367	CcSEcCtD
Methyl aminolevulinate—Dizziness—Etoposide—sarcoma	0.00284	0.00356	CcSEcCtD
Methyl aminolevulinate—Erythema—Doxorubicin—sarcoma	0.00273	0.00342	CcSEcCtD
Methyl aminolevulinate—Rash—Etoposide—sarcoma	0.00271	0.0034	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Etoposide—sarcoma	0.0027	0.00339	CcSEcCtD
Methyl aminolevulinate—Headache—Etoposide—sarcoma	0.00269	0.00337	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FOXO1—sarcoma	0.00266	0.0131	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PDGFRB—sarcoma	0.00265	0.0131	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PDGFRA—sarcoma	0.00261	0.0128	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FOXO1—sarcoma	0.00255	0.0126	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Etoposide—sarcoma	0.00255	0.0032	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PDGFRB—sarcoma	0.00255	0.0125	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL2—sarcoma	0.00254	0.0125	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PDGFRA—sarcoma	0.00251	0.0123	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Epirubicin—sarcoma	0.00248	0.00311	CcSEcCtD
Methyl aminolevulinate—Oedema—Epirubicin—sarcoma	0.00241	0.00302	CcSEcCtD
Methyl aminolevulinate—Infection—Epirubicin—sarcoma	0.00239	0.003	CcSEcCtD
Methyl aminolevulinate—Discomfort—Doxorubicin—sarcoma	0.00229	0.00288	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PTPRC—sarcoma	0.00223	0.011	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Doxorubicin—sarcoma	0.00223	0.00279	CcSEcCtD
Methyl aminolevulinate—Infection—Doxorubicin—sarcoma	0.00221	0.00277	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PLCG1—sarcoma	0.00218	0.0107	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Epirubicin—sarcoma	0.00216	0.00271	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—NRAS—sarcoma	0.00213	0.0105	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Epirubicin—sarcoma	0.00207	0.0026	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ATF1—sarcoma	0.00207	0.0102	CbGpPWpGaD
Methyl aminolevulinate—Pain—Epirubicin—sarcoma	0.00206	0.00258	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KIT—sarcoma	0.00202	0.00996	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Doxorubicin—sarcoma	0.002	0.00251	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KIT—sarcoma	0.00194	0.00957	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CREB1—sarcoma	0.00193	0.00948	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Doxorubicin—sarcoma	0.00192	0.00241	CcSEcCtD
Methyl aminolevulinate—Urticaria—Epirubicin—sarcoma	0.00191	0.0024	CcSEcCtD
Methyl aminolevulinate—Pain—Doxorubicin—sarcoma	0.0019	0.00239	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CREB1—sarcoma	0.00185	0.00911	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—KRAS—sarcoma	0.00183	0.00903	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Epirubicin—sarcoma	0.00177	0.00222	CcSEcCtD
Methyl aminolevulinate—Urticaria—Doxorubicin—sarcoma	0.00177	0.00222	CcSEcCtD
Methyl aminolevulinate—Asthenia—Epirubicin—sarcoma	0.00173	0.00217	CcSEcCtD
Methyl aminolevulinate—Pruritus—Epirubicin—sarcoma	0.0017	0.00214	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Doxorubicin—sarcoma	0.00164	0.00206	CcSEcCtD
Methyl aminolevulinate—Asthenia—Doxorubicin—sarcoma	0.0016	0.002	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MDM2—sarcoma	0.00159	0.00785	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Epirubicin—sarcoma	0.00159	0.002	CcSEcCtD
Methyl aminolevulinate—Pruritus—Doxorubicin—sarcoma	0.00157	0.00198	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HRAS—sarcoma	0.00156	0.00768	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FOXO1—sarcoma	0.00155	0.00762	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PDGFRB—sarcoma	0.00154	0.0076	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—MDM2—sarcoma	0.00153	0.00753	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PDGFRA—sarcoma	0.00152	0.00748	CbGpPWpGaD
Methyl aminolevulinate—Rash—Epirubicin—sarcoma	0.00152	0.0019	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Epirubicin—sarcoma	0.00152	0.0019	CcSEcCtD
Methyl aminolevulinate—Headache—Epirubicin—sarcoma	0.00151	0.00189	CcSEcCtD
Methyl aminolevulinate—Dizziness—Doxorubicin—sarcoma	0.00147	0.00185	CcSEcCtD
Methyl aminolevulinate—Nausea—Epirubicin—sarcoma	0.00143	0.00179	CcSEcCtD
Methyl aminolevulinate—Rash—Doxorubicin—sarcoma	0.0014	0.00176	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Doxorubicin—sarcoma	0.0014	0.00176	CcSEcCtD
Methyl aminolevulinate—Headache—Doxorubicin—sarcoma	0.00139	0.00175	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—JUN—sarcoma	0.00139	0.00682	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CTNNB1—sarcoma	0.00137	0.00677	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Doxorubicin—sarcoma	0.00132	0.00166	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—SRC—sarcoma	0.00124	0.00612	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—NRAS—sarcoma	0.0012	0.00589	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRC—sarcoma	0.00119	0.00587	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KIT—sarcoma	0.00118	0.0058	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—NRAS—sarcoma	0.00115	0.00565	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CREB1—sarcoma	0.00112	0.00552	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGFR—sarcoma	0.00109	0.00536	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGFR—sarcoma	0.00105	0.00515	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KRAS—sarcoma	0.00103	0.00507	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KRAS—sarcoma	0.000988	0.00486	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MDM2—sarcoma	0.000928	0.00457	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HRAS—sarcoma	0.000875	0.00431	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HRAS—sarcoma	0.00084	0.00413	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL2—sarcoma	0.00083	0.00408	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—JUN—sarcoma	0.000807	0.00397	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTNNB1—sarcoma	0.000801	0.00394	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SRC—sarcoma	0.000724	0.00356	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—NRAS—sarcoma	0.000696	0.00343	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EGFR—sarcoma	0.000634	0.00312	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KRAS—sarcoma	0.000599	0.00295	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HRAS—sarcoma	0.000509	0.00251	CbGpPWpGaD
